Navigation Links
Hemophilia research gets NIH boost to a tune of $5.5 million
Date:9/2/2011

At a time when research funding is hard to come by, a University of Central Florida and University of Florida partnership has landed almost $5.5 million in National Institutes of Health highly competitive grants for hemophilia research.

The first grant worth $3.6 million over five years is aimed at determining whether a green technique pioneered at UCF will help make treatment of hemophilia A more effective. The second grant worth $2 million for four years is for similar research for hemophilia B. The grants were awarded to UCF and UF, which applied for funding jointly thanks to a long-time collaboration between scientists at both institutions. Duke University also is a partner for the research on hemophilia A.

Hemophilia is an incurable bleeding condition that affects about 400,000 adults and children worldwide. Hemophilia is characterized by defects in the gene that produces proteins required for blood to clot. Hemophilia A, the most common type of hemophilia, is characterized by prolonged or spontaneous bleeding, especially in the muscles, joints or internal organs.

Treating hemophilia is challenging and dangerous because many patients suffer fatal allergic reactions to the protein that doctors use to facilitate blood clotting. The scientists are working on a way to make patients resistant to any deadly allergic reactions caused by the protein.

Treatments with the protein are also expensive. They must be provided in a hospital setting under supervision, and they can cost up to $1 million over a patient's lifetime because of the required hospital stays and blood transfusions. Average annual treatment costs are $60,000 to $150,000, according to the National Hemophilia Foundation.

"I am confident we will achieve success sooner than you think," said UCF Professor Henry Daniell. "We are hopeful that this technique will potentially save thousands of lives."

The researchers are using genetically modified plants to encapsulate a tolerance-inducing protein within plant cells so the protein could be ingested and safely travel through the stomach before being released into the small intestines, where the immune system can act on it.

In mice with hemophilia B, when blood clotting factor IX bio-encapsulated within plant cells was delivered to the gut, it prevented fatal anaphylactic shock and complex immune reactions. The new NIH funding, which came through the National Lung, Blood and Heart Institute, will help propel the research to determine if the technique can work in other models and potentially to clinical trials thereafter.

"The collaboration has an excellent chance of developing treatments that improve the lives of people with hemophilia and, at the same time, help lower health care costs," said Roland Herzog, a professor at UF.

After Daniell mentored Herzog at Auburn University, Herzog went on to develop his career. He has received multiple awards for his research in hematology including several NIH grants, a career development award from the National Hemophilia Foundation, an outstanding investigator award from the American Society of Gene Therapy and a Bayer Hemophilia Award.

Both researchers are hopeful that if future research bears out, this approach would be much safer and potentially deliver less expensive treatments to thousands who live with this disease.

While the approach is cutting edge, the NIH funding has come after Daniell and Herzog's research was featured last year in Proceedings of the National Academy of Sciences, a highly acclaimed scientific journal. Bayer Healthcare of Germany, the world's largest funder of hemophilia research, also gave Daniell a $200,000 grant in 2010 for research exploring the novel concept.

Daniell is conducting similar research on a polio vaccine funded by the Bill and Melinda Gates Foundation and on diabetes funded by the Juvenile Diabetes Research Foundation.

"The clinical translation of our work is closely tied with other projects in our lab, and all are showing promising results. So I am very hopeful that this concept and technology will move forward soon," Daniell said.


'/>"/>

Contact: Zenaida Gonzalez Kotala
zenaida.kotala@ucf.edu
407-823-6120
University of Central Florida
Source:Eurekalert  

Related biology news :

1. UT scientist receives hemophilia research award
2. Researchers harness the power of plants to fight hemophilia
3. Yale develops new animal model for hemophilia A
4. Early safety results promising for Phase I/II trial of gene therapy treatment of hemophilia B
5. Genome editing, a next step in genetic therapy, corrects hemophilia in animals
6. New NJIT book examines hemophilia and consequences of medical progress
7. Wistar Institute researcher receives New Innovator award from NIH
8. NC State researchers get to root of parasite genome
9. White Mountain Research Station to host climate change conference
10. Stevens awarded $1M for advanced biofuels research
11. Researchers find animal with ability to survive climate change
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Hemophilia research gets NIH boost to a tune of $5.5 million
(Date:7/20/2017)... Delta (NYSE: DAL ) customers now can use ... Reagan Washington National Airport (DCA). ... Delta launches biometrics to board aircraft at Reagan Washington ... Delta,s biometric boarding pass experience that ... integrated into the boarding process to allow eligible Delta SkyMiles Members who ...
(Date:5/23/2017)... May 23, 2017  Hunova, the first robotic gym for the rehabilitation ... officially launched in Genoa, Italy . The first 30 ... and the USA . The technology was developed and ... by the IIT spin-off Movendo Technology thanks to a 10 million euro ... Release, please click: ...
(Date:4/24/2017)... 24, 2017 Janice Kephart , ... Identity Strategy Partners, LLP (IdSP) , today issues ... President Trump,s March 6, 2017 Executive Order: ... vetting can be instilled with greater confidence, enabling ... all refugee applications are suspended by until at ...
Breaking Biology News(10 mins):
(Date:10/12/2017)... ... October 12, 2017 , ... ... a United States multicenter, prospective clinical study that demonstrates the accuracy of ... capable of identifying clinically significant acute bacterial and viral respiratory tract infections ...
(Date:10/11/2017)... ... October 11, 2017 , ... At its national board meeting ... I. Sheikh, the co-founder, CEO and chief research scientist of Minnesota-based Advanced Space ... membership in ARCS Alumni Hall of Fame . ASTER Labs is a ...
(Date:10/11/2017)... ... October 11, 2017 , ... ... it will be hosting a Webinar titled, “Pathology is going digital. Is your ... on digital pathology adoption best practices and how Proscia improves lab economics and ...
(Date:10/11/2017)... ... October 11, 2017 , ... A new study published ... frozen and fresh in vitro fertilization (IVF) transfer cycles. The multi-center ... success. , After comparing the results from the fresh and frozen transfer cohorts, ...
Breaking Biology Technology: